Plain-English translation of NCT07220460 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new investigational medication called to see how well it works and how safe it is for adults experiencing a depressive episode related to bipolar I or II disorder. About 200 people will take this medication for 26 weeks at study sites across the United States and Puerto Rico. The researchers will carefully monitor participants to understand the medication's benefits and any side effects.
Bipolar disorder is a serious, long-lasting mood condition that affects millions of Americans, and depressive episodes can be particularly difficult to treat. This study aims to find out whether this new treatment might offer a safer or more effective option for people struggling with bipolar depression.
You likely qualify if…
You likely don't qualify if…
You will take oral capsules of the medication daily for 26 weeks, then return for a 30-day follow-up visit. During the study, you'll attend regularly scheduled clinic visits where doctors will check your symptoms through questionnaires, blood tests, vital signs, and heart monitoring to make sure the medication is working and that you're staying safe. This trial may require more frequent visits than your regular care, so it's important to confirm you can commit to the schedule.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States